|
gptkbp:instance_of
|
gptkb:vaccine
|
|
gptkbp:bfsLayer
|
5
|
|
gptkbp:bfsParent
|
gptkb:Zoster_vaccine
|
|
gptkbp:activities
|
induces immunity
|
|
gptkbp:appointed_by
|
subcutaneous injection
|
|
gptkbp:approves
|
gptkb:1995
gptkb:FDA
|
|
gptkbp:clinical_trial
|
ongoing
|
|
gptkbp:contains
|
live attenuated virus
|
|
gptkbp:contraindication
|
pregnant women
immunocompromised individuals
|
|
gptkbp:developed_by
|
gptkb:Merck_&_Co.
|
|
gptkbp:dosage_form
|
not routinely required
one dose for children
|
|
gptkbp:healthcare
|
gptkb:significant
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
live attenuated varicella-zoster virus
|
|
gptkbp:indication
|
chickenpox vaccination
|
|
gptkbp:is_effective_against
|
over 90%
favorable
|
|
gptkbp:is_used_for
|
prevention of chickenpox
|
|
gptkbp:is_vulnerable_to
|
high
global
important
increasing
live attenuated vaccine
addressed
second dose at 4-6 years
recommended at 12-15 months
|
|
gptkbp:market
|
conducted
|
|
gptkbp:marketed_as
|
gptkb:legislation
gptkb:United_States
gptkb:Native_American_tribe
|
|
gptkbp:recommendation
|
gptkb:CDC
gptkb:WHO
|
|
gptkbp:research_focus
|
long-term immunity
vaccine efficacy
safety in special populations
|
|
gptkbp:safety_features
|
well-studied
|
|
gptkbp:side_effect
|
rare
fever
mild rash
|
|
gptkbp:social_responsibility
|
gptkb:varicella
shingles
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:suitable_for
|
gptkb:Person
|
|
gptkbp:traded_on
|
gptkb:Varivax
|